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In human serum immunoglobulin G (IgG), a rare modification of
biantennary complex N-glycans lead to a β1,4-galactosylated
bisecting GlcNAc branch. We found that the bisecting GlcNAc
on a biantennary core-fucosylated N-glycan was enzymatically
galactosylated under stringent reaction conditions. Further
optimizations led to an efficient enzymatic approach to this
particular modification for biantennary substrates. Notably, tri-
and tetra-antennary complex N-glycans were not converted by
bovine galactosyltransferase. An N-glycan with a galactosylated
bisecting GlcNAc was linked to a lanthanide binding tag. The
pseudo-contact shifts (PCS) obtained from the corresponding
Dy-complex were used to calculate the conformational prefer-
ences of the rare N-glycan. Besides two extended conforma-
tions only a single folded conformation was found.
Introduction
Immunoglobulins are one of the best-studied classes of
glycoproteins due to their high therapeutic value. The N-
glycans of immunoglobulins are known to affect the biological
activity of antibodies, for example, by modulating the inter-
actions of the Fc part.[1] Thus, the glycosylation pattern of
therapeutic antibodies is thoroughly characterized. Originating
from an unexpected side reaction during the enzymatic
galactosylation of a synthetic bisected N-glycan we became
aware that galactosylated bisecting GlcNAc moieties are present
in human serum IgG. The Gal-β1,4-bisecting GlcNAc motif was
initially discovered by Nishimura[2] and later confirmed by
Rudd[3] (Scheme 1). A similar motif was also found on bisected
hybrid N-glycans of the 19 A glycoprotein derived from a lectin-
resistant HEK cell line.[3] In cells lacking GlcNAc-transferase II the
truncated bisected N-glycans leads to a Gal-β1,4-bisecting
GlcNAc motif, which can be further modified.[4] An enzymatic
galactosylation of a single GlcNAc β1,2-linked to the central β-
mannose was found for a synthetic N-glycan bearing the LEC 14
antigen.[5]
Results and Discussion
As part of a collaboration with the Consortium for Functional
Glycomics (CFG), we synthesized various bisected complex-type
N-glycans and functionalized them with a bifunctional spacer
for glycan microarray printing.[6] The bisected N-glycans[7] were
synthesized chemically following a modular approach and
deprotected to the free N-glycans.
In the case of the core fucosylated bisected compound 4,
precursor 1 was obtained from three building blocks[8] and was
subsequently fucosylated using thiofucoside 2[9] (Scheme 2).
The low stereoselectivity (α/β ratio 5.4 : 1) required the separa-
tion of the unnatural β-anomer 3b by preparative HPLC.
Subsequently, the protecting groups of nonasaccharide 3 were
removed in a multistep procedure. After treatment with ethyl-
enediamine in n-butanol an acetylation/deacetylation sequence
yielded a benzylated nonasaccharide azide intermediate, which
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Scheme 1. Biantennary N-glycan with unmodified bisecting GlcNAc (A);
complex N-glycans found on human serum IgG bearing a β1,4-galactosy-
lated bisecting GlcNAc motif (B, C); hybrid N-glycans from 19 A glycoprotein
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was reduced to the anomeric amine using propanedithiol.[10]
Complete removal of residual thiol was crucial prior to acidic
hydrolysis of the glycosylamine. The final catalytic hydro-
genation gave the free N-glycan 4 in good overall yield. The
enzymatic galactosylation of 4 was carried out using UDP-Gal,
bovine galactosyltransferase and calf alkaline phosphatase
(CIAP).[11] Analysis of the reaction mixture after three days by
MALDI-TOF-MS showed the desired galactosylated N-glycan 5
but also a side product (ca. 23%) with the mass of an additional
galactose unit and we assumed that the additional galactose
might be attached to the bisecting GlcNAc (6). We noticed that
relative to previous galactosylations of biantennary bisected N-
glycan-conjugates[12] the concentration of the N-glycan acceptor
(4) was higher (4x) as well as the relative amount of
galactosyltransferase (2x). Using even higher concentrations of
N-glycan acceptor 4 and repeated addition of galactosyltrans-
ferase gave nearly complete conversion to the trigalactosylated
product 6. On a preparative scale 4 (3.7 mg; 19 mM) was
incubated with 800 mU of galactosyltransferase added in three
portions over 9 days, which led to complete conversion
according to MALDI-TOF-MS. The trigalactosylated compound 6
was isolated by gel filtration in a yield of 74%. Using a lower
concentration of 4 in combination with lower amounts of
galactosyltransferase furnished the selectively digalactosylated
compound 5 in 78% yield.
Both compounds 5 and 6 were characterized by a set of 2D
NMR experiments revealing that the third galactose was indeed
transferred to O-4 of the bisecting GlcNAc moiety. This was
evident from the 1H signal of H-4B shifting from 3.06 to 3.3 ppm
and the 13C signal of C-4B moving from 72.7 to 81.7 ppm
indicative for a glycosylation at C4B. The glycans 5 and 6 were
equipped with a bifunctional linker and added to the repertoire
of the CFG glycan array (data not shown).
Next the scope of the enzymatic elongation of a bisecting
GlcNAc was investigated on an analytical scale using a series of
fully synthetic bisected N-glycan azides (Scheme 3). The panel
of potential substrates consisted of the unsubstituted bisected
N-glycan 7,[7] the corresponding core-fucosylated glycan 8[8] and
bisected compounds with three or four antennae (9–11).[7]
When attempting to apply the stringent conditions of galacto-
sylation directly to the acceptors (19 mM 7–11), strong
substrate inhibition was found, which only led to sluggish and
incomplete galactosylation after several days (HPLC data not
shown). In contrast, dilute conditions (2 mM acceptor 7–11)
gave complete galactosylation of the GlcNAc termini within
1 day (12–16). The galactosylated compounds were submitted
Scheme 2. Synthesis of N-glycan 3, deprotection to hemiacetal 4 and
enzymatic galactosylation to 5 and 6. The numbering of the residues for
NMR assignments is shown for 6.
Scheme 3. The panel of bisected N-glycan azides (7–11) was enzymatically
galactosylated under dilute (1.) and subsequently under stringent (2.)
conditions. Transfer of an additional galactose to the bisecting GlcNAc was
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to stringent galactosylation conditions (19 mM acceptor 12–16).
Out of the five compounds only the biantennary N-glycans 12
and 13 gave the corresponding product with a galactosylated
bisecting GlcNAc (17–18) whereas no conversion according to
LC–MS was found for the compounds with three or four
antennae (9–11). The galactosylation of a bisecting GlcNAc
appears to be particularly sensitive to additional steric hin-
drance and might not be possible in the case of complex N-
glycans with more than two antennae. According to the HPLC
peak areas of the galactosylations after 3 days, the transfer of
the third galactose occurs significantly more slowly (~1/5) in
the presence of a core fucose (13) compared with the
unsubstituted bisected compound (12) (see S4 in the Support-
ing Information).
Because only the biantennary digalactosylated N-glycan
azides were accepted by galactosyltransferase, we assumed
that the galactosylated bisecting GlcNAc residue might affect
the conformational freedom of the neighboring antennae. We
decided to investigate the conformational preferences of the N-
glycan 17 by attaching a suitable lanthanide binding tag (19)
and subsequently measure the pseudo contact shifts of para-
magnetic N-glycan complexes to calculate the preferred
conformations.[13] On a preparative scale the bisected octasac-
charide azide 7 was first converted to the digalactosylated
compound 12 (92% yield) and subsequently to the trigalactosy-
lated undecasaccharide 17 (91% after RP-HPLC). The azide of
17 was reduced and coupled with the lanthanide binding tag
18. Purification of the conjugate 19 by RP-HPLC was important
at this stage since a small percentage (~12%) of α-configured
product also formed. The ethyl esters of 19 were saponified in
1 M NaOH followed by a purification of 20 by RP-HPLC and
complexation with either LaCl3 or DyCl3 in a D2O-imidazole
buffer (Scheme 4.[13b]
The conformational behavior of the trigalactosylated bi-
sected N-glycan 17 was characterized by using paramagnetic
NMR.[14] We have previously implemented this approach to
determine the conformation of a non-bisected biantennary N-
glycan and the same methodology has been employed in this
work.[13a] The good HSQC-signal dispersion obtained for the
paramagnetic dysprosium complex 20b allowed full resolution
of the anomeric signals of GlcNAc residues 5 and 5’ and the
three galactoses (G, G’ and GB), which overlapped in the
diamagnetic complex 20a (Scheme 5A, B). In total 58 PCSs were
obtained and used for conformation analysis (Scheme 5C). The
PCS depends on the distance and the orientation of the NMR
nuclei relative to the paramagnetic metal ion and thus provides
structural information. The experimental PCs were correlated
with the back-calculated values from the different minimum
energy conformations of the N-glycan by using Mspin
software.[15] Iterative calculations were carried out with Mspin to
obtain the number of conformers and the population of each
conformer that better fit the experimental PCS values. The best
correlation between experimental and calculated data was
obtained considering three interconverting main conformations
for the Man4’α1,6-Man3 linkage, extended gauche–gauche (gg),
extended gauche–trans (gt) and folded gg conformation, with
populations of 40, 28, and 32%, respectively (Scheme 5D).
Scheme 4. Synthesis of the trigalactosylated bisected N-glycan azide 17,
conjugation with lanthanide binding tag 18, deprotection and formation of
the diamagnetic complex 20a and the paramagnetic complex 20b.
Scheme 5. A), B) HSQC sections of the anomeric region of the diamagnetic
(20a) and paramagnetic complex (20b); the three galactose signals are
within the dotted lines. C) PCS of paramagnetic complex 20b. D) Relative
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The main conformations are the extended gg and gt
conformers as also found in the corresponding non-bisected
biantennary N-glycan.[13a] However, a higher population (32%)
of a single folded conformation (ψ=90°) was obtained for the
galactosylated bisected glycan compared with the non-bisected
biantennary structure, where two folded conformations were
found (10% ψ=60° and 10% ψ=90°). Notably, the galactosy-
lated bisected branch affects the preferred conformations of
the N-glycan leading to a threefold increase of a single folded
geometry of the α1,6 arm. The extended gt conformation
served as a starting point for a preliminary model where the
bisecting GlcNAc of 12 could be placed in the acceptor site of
bovine galactosyltransferase (PDB ID: 1TW5)[16] with only minor
adjustments of the 1,3 arm (see Schemes S7 and S8 in the
Supporting Information). We are currently investigating the
conformational preferences of complex N-glycans with the
typical bisecting GlcNAc-modification lacking the additional
galactose unit.
In summary a rare N-glycan identified in human serum IgG
could be synthesized by using stringent conditions for the
enzymatic galactosylation of the bisecting GlcNAc moiety. This
particular conversion appears to be limited to biantennary-N-
glycans. The conformational analysis of a conjugate of the
glycan bearing the galactosylated bisecting GlcNAc motif using
paramagnetic NMR revealed two extended conformers but only
a single folded geometry.
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